BRNS vs. ANIX, SPRO, BYSI, CMRX, MIST, CUE, ONCY, ADAG, PRPH, and YS
Should you be buying Barinthus Biotherapeutics stock or one of its competitors? The main competitors of Barinthus Biotherapeutics include Anixa Biosciences (ANIX), Spero Therapeutics (SPRO), BeyondSpring (BYSI), Chimerix (CMRX), Milestone Pharmaceuticals (MIST), Cue Biopharma (CUE), Oncolytics Biotech (ONCY), Adagene (ADAG), ProPhase Labs (PRPH), and YS Biopharma (YS). These companies are all part of the "pharmaceutical preparations" industry.
Barinthus Biotherapeutics (NASDAQ:BRNS) and Anixa Biosciences (NASDAQ:ANIX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk, institutional ownership and community ranking.
Barinthus Biotherapeutics presently has a consensus price target of $8.00, indicating a potential upside of 240.43%. Anixa Biosciences has a consensus price target of $12.00, indicating a potential upside of 321.05%. Given Anixa Biosciences' higher probable upside, analysts clearly believe Anixa Biosciences is more favorable than Barinthus Biotherapeutics.
25.2% of Barinthus Biotherapeutics shares are held by institutional investors. Comparatively, 29.1% of Anixa Biosciences shares are held by institutional investors. 8.0% of Barinthus Biotherapeutics shares are held by insiders. Comparatively, 22.6% of Anixa Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Anixa Biosciences received 12 more outperform votes than Barinthus Biotherapeutics when rated by MarketBeat users. However, 100.00% of users gave Barinthus Biotherapeutics an outperform vote while only 64.29% of users gave Anixa Biosciences an outperform vote.
In the previous week, Barinthus Biotherapeutics had 9 more articles in the media than Anixa Biosciences. MarketBeat recorded 11 mentions for Barinthus Biotherapeutics and 2 mentions for Anixa Biosciences. Anixa Biosciences' average media sentiment score of 1.27 beat Barinthus Biotherapeutics' score of 0.96 indicating that Anixa Biosciences is being referred to more favorably in the news media.
Barinthus Biotherapeutics' return on equity of -36.61% beat Anixa Biosciences' return on equity.
Anixa Biosciences has lower revenue, but higher earnings than Barinthus Biotherapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Barinthus Biotherapeutics, indicating that it is currently the more affordable of the two stocks.
Barinthus Biotherapeutics has a beta of -0.45, indicating that its stock price is 145% less volatile than the S&P 500. Comparatively, Anixa Biosciences has a beta of 0.86, indicating that its stock price is 14% less volatile than the S&P 500.
Summary
Anixa Biosciences beats Barinthus Biotherapeutics on 9 of the 16 factors compared between the two stocks.
Get Barinthus Biotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BRNS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BRNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Barinthus Biotherapeutics Competitors List
Related Companies and Tools
